SCHEMBL260818

SCHEMBL260818

O=C1N=c2cccnc2=N1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.37
TDP2 O95551 1/20 0.37
NSD2 O96028 1/20 0.37
ABL1 P00519 1/20 0.37
PLCG1 P19174 1/20 0.37
CES1 P23141 1/20 0.37
PAX8 Q06710 1/20 0.37
RIN1 Q13671 1/20 0.37
MEN1 O00255 1/20 0.37
THRB P10828 1/20 0.37
BLM P54132 1/20 0.37
KMT2A Q03164 1/20 0.37
GAA P10253 1/20 0.37
CDC25B P30305 3/20 0.33
PTPRC P08575 2/20 0.33
S100A4 P26447 2/20 0.33
CTSL P07711 1/20 0.33
CTSS P25774 1/20 0.33
PTPN13 Q12923 1/20 0.33
KDM4E B2RXH2 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL26638317 0.98 TDP1 (0.35) TDP1TDP2NSD2ABL1PLCG1
SCHEMBL1133597 0.82 TDP1 (0.37) TDP1TDP2NSD2ABL1PLCG1
SCHEMBL29599407 0.80 TDP1 (0.35) TDP1TDP2NSD2ABL1PLCG1
SCHEMBL31050548 0.73 KDM4E (0.31) TDP1KDM4EMAPTGMNNLMNA
SCHEMBL4646997 0.73 HTT (0.34) TDP1KDM4EMAPTGMNNLMNA
SCHEMBL27748770 0.73 KDM4E (0.31) TDP1KDM4EMAPTGMNNLMNA
SCHEMBL37950 0.72 MEN1 (0.35) TDP1TDP2PLCG1CES1MEN1
SCHEMBL247141 0.72
SCHEMBL28072669 0.72 MEN1 (0.35) TDP1TDP2PLCG1CES1MEN1
SCHEMBL2935846 0.71 TDP2 (0.32) TDP1TDP2NSD2ABL1PLCG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059955-A Imidazo pyridone compound, photocatalysis continuous synthesis method and application thereof 南京工业大学 2026-05-19 CN claimed
CN-118994151-A Imidazopyridone compounds binding to sigma-2 receptor, preparation method and application thereof 北京师范大学 2024-11-22 CN claimed
CN-116574101-A Method for continuously preparing imidazopyridone compounds by photocatalysis 南京工业大学 2023-08-11 CN claimed
EP-3523311-B1 SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-06-07 EP claimed
CN-113164618-A Methods and compositions for treating diseases with immunostimulatory conjugates 希沃尔拜克治疗公司 2021-07-23 CN claimed
EP-3849615-A1 COMPOSITIONS FOR THE TREATMENT OF DISEASE WITH IMMUNE STIMULATORY CONJUGATES Silverback Therapeutics, Inc. (US) 2021-07-21 EP claimed
EP-3833663-A1 PESTICIDALLY-ACTIVE BICYCLIC HETEROAROMATIC COMPOUNDS Syngenta Crop Protection AG (CH) 2021-06-16 EP claimed
WO-2020056008-A1 COMPOSITIONS FOR THE TREATMENT OF DISEASE WITH IMMUNE STIMULATORY CONJUGATES SILVERBACK THERAPEUTICS, INC. (US) 2020-03-19 WO claimed
WO-2020030503-A1 PESTICIDALLY-ACTIVE BICYCLIC HETEROAROMATIC COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2020-02-13 WO claimed
EP-3523311-A1 SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2019-08-14 EP claimed
WO-2008051493-A2 HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2008-05-02 WO claimed
US-20070219197-A1 Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives ASTELLAS PHARMA GMBH (DE) 2007-09-20 US claimed
US-20070142377-A1 Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives BIEDERMANN ELFI 2007-06-21 US claimed
WO-2007028524-A2 USE OF A DERIVATIVE OF IMIDAZOLE FOR THE TREATMENT OF LEUKOTRIENE RELATED DISORDERS PROUS INSTITUTE FOR BIOMEDICAL RESEARCH S.A. (ES) 2007-03-15 WO claimed
WO-2005011697-A2 SULFONAMIDE DERIVATIVES WITH ACTIVITY ON PROTEIN KINASE A AND B ASTEX THERAPEUTICS LIMITED (GB) 2005-02-10 WO claimed
US-20040176605-A1 New pyridyl alkane acid amides as cytostatics and immunosuppressives KLINGE PHARMA GMBH 2004-09-09 US claimed
US-20040029861-A1 Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression KLINGE PHARMA GMBH 2004-02-12 US claimed
US-20040009967-A1 Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immuno-suppressives KLINGE PHARMA GMBH 2004-01-15 US claimed
US-20030162972-A1 Pyridyl alkane acid amides as cytostatics and immunosupressives KLINGE PHARMA GMBH 2003-08-28 US claimed
US-4806560-A ANTIHISTAMINES AND ANTISEROTONINE AGENTS SYNTHELABO (FR) 1989-02-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176605-A1 New pyridyl alkane acid amides as cytostatics and immunosuppressives ALK, ANXA1, ANXA11 TDP1 2250/4885TDP2 3131/4885NSD2 3130/4885
US-20070219197-A1 Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives NFATC1, PDCD1, ACIN1 TDP1 1766/4885TDP2 2335/4885NSD2 3557/4885
US-20040009967-A1 Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immuno-suppressives IDO1, ALK, ARG1 TDP1 2072/4885TDP2 2651/4885NSD2 3349/4885
US-20040029861-A1 Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression ALK, IDO1, PDXK TDP1 1937/4885TDP2 2821/4885NSD2 3679/4885
US-20030162972-A1 Pyridyl alkane acid amides as cytostatics and immunosupressives ALK, TYMP, ANXA1 TDP1 2022/4885TDP2 3147/4885NSD2 3120/4885
US-20070142377-A1 Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives ALK, TYMP, PDCD1 TDP1 2047/4885TDP2 2723/4885NSD2 3428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.